120 related articles for article (PubMed ID: 7682951)
1. Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.
Mead GM; Stenning SP
Eur Urol; 1993; 23(1):196-200; discussion 201. PubMed ID: 7682951
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.
Lancet; 1985 Jan; 1(8419):8-11. PubMed ID: 2578205
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
5. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
[TBL] [Abstract][Full Text] [Related]
6. Current optimum management of anaplastic germ cell tumours of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Br J Urol; 1986 Jun; 58(3):307-14. PubMed ID: 2424538
[TBL] [Abstract][Full Text] [Related]
7. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
Horwich A; Brada M; Nicholls J; Jay G; Hendry WF; Dearnaley D; Peckham MJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
[TBL] [Abstract][Full Text] [Related]
8. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
9. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience.
Stoter G; Sleijfer D; Kaye SB; Jones WG; ten Bokkel Huinink WW; de Pauw M; Sylvester R
Eur Urol; 1993; 23(1):202-6. PubMed ID: 8386650
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
13. Germ cell tumours of testis: prognostic factors and results.
Nikzas D; Champion AE; Fox M
Eur Urol; 1990; 18(4):242-7. PubMed ID: 1705226
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor markers and testicular germ cell tumors: a primer for radiologists.
Marshall C; Enzerra M; Rahnemai-Azar AA; Ramaiya NH
Abdom Radiol (NY); 2019 Mar; 44(3):1083-1090. PubMed ID: 30539249
[TBL] [Abstract][Full Text] [Related]
15. The present and future of serum diagnostic tests for testicular germ cell tumours.
Murray MJ; Huddart RA; Coleman N
Nat Rev Urol; 2016 Dec; 13(12):715-725. PubMed ID: 27754472
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic testicular cancer.
Vogelzang NJ
Int J Androl; 1987 Feb; 10(1):225-37. PubMed ID: 2438220
[TBL] [Abstract][Full Text] [Related]
17. Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours.
O'Reilly SM; Rustin GJ; Smith DB; Newlands ES
Ann Oncol; 1992 Feb; 3(2):163-4. PubMed ID: 1376619
[TBL] [Abstract][Full Text] [Related]
18. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
Seckl MJ; Rustin GJ; Bagshawe KD
Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
[TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
